Other languages 10x Genomics, Inc.

Equities

TXG

US88025U1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
22.19 ^USD	+3.16%		+0.36%	-60.35%

Jun. 03	Jefferies Initiates 10x Genomics at Hold Rating With $24 Price Target	MT
May. 29	10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium	May. 29
Bruker's NanoString Secures Patent Case Win in Germany	May. 07
10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024	Apr. 30
10x Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30
10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay	Mar. 26
10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel	Mar. 21
10x Genomics Launches Two New Products With Single Cell Technology	Mar. 13
10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products	Mar. 13
10x Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
10x Genomics Q4 Net Loss Widens, Revenue Increases; Issues Outlook	Feb. 15
10x Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15
10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024	Feb. 15
10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology	Feb. 07
NanoString Starts Chapter 11 Bankruptcy; Exploring Strategic Options, Including Potential Sale	Feb. 05
James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024	Jan. 16
10x Genomics Reports Preliminary Q4, Full Year 2023 Revenue	Jan. 08
10x Genomics Launches Network to Accelerate Access to Xenium Proof-of-Concept Data	Dec. 21
10x Genomics Insider Sold Shares Worth $619,494, According to a Recent SEC Filing	Nov. 22
NanoString Technologies Withdraws Q4, Full-Year Outlook Following Jury's Verdict in Patent Dispute With 10x Genomics	Nov. 20
OWKIN Integrates 10x Genomics, Inc. Spatial Omics and Single-Cell Technologies to the MOSAIC Study	Nov. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 10x Genomics, Inc.

Equities

TXG

US88025U1097

Other languages

Filters